Carney complex is a rare inherited syndrome that predisposes people to a distinctive combination of tumors, hormone imbalances, and pigmented skin lesions scattered across the body. First described in 1985 by pathologist J. Aidan Carney at the Mayo Clinic, it was originally called “the complex of myxomas, spotty pigmentation, and endocrine overactivity,” and that triad still captures the essence of the condition.1CASE. Diagnosing Diseases A Tuberculosis Case Is Discovered to Be Carney Complex Instead Most cases trace to mutations in a single gene, PRKAR1A, which acts as a brake on a key cellular growth-signaling pathway. When that brake fails, tissues throughout the body become prone to abnormal growth, making Carney complex a condition that touches the heart, skin, adrenal glands, pituitary, thyroid, and gonads all at once.
The Genetic Root
Carney complex follows an autosomal dominant inheritance pattern, meaning a single copy of a faulty gene inherited from either parent is enough to cause the disease. The primary culprit is the PRKAR1A gene, located on chromosome 17q22-24, which encodes a regulatory subunit of protein kinase A (PKA). PKA is a signaling enzyme involved in cell growth and hormone production across many tissues. When PRKAR1A is intact, it restrains PKA activity. When PRKAR1A is lost or disabled, PKA runs unchecked.2PubMed. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex
The mutations themselves are diverse. In an early study of affected families, researchers identified 14 different sequence changes that each introduced a premature stop signal in the gene’s instructions, plus one that disrupted the very start of the protein’s recipe. In every case, the defective copies of the gene’s message were destroyed inside the cell before they could produce a truncated protein, a cleanup process known as nonsense-mediated decay. The practical outcome is the same regardless of the specific mutation: the regulatory subunit simply is not made, and PKA becomes overactive.3PubMed. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex
A second genetic locus on chromosome 2p16 has also been linked to Carney complex, though no specific gene at that site has been definitively identified. Studies of tumors from Carney complex patients have found consistent chromosomal changes in the 2p16 region, including amplification and deletion, in a high proportion of samples, even among patients who already carry PRKAR1A mutations.4PubMed Central. Chromosome 2 (2p16) abnormalities in Carney complex tumours This means the condition is genetically heterogeneous: most families carry PRKAR1A mutations, but a subset appear to have a different genetic driver at 2p16, and the 2p16 region may play a role in tumor development regardless of which primary mutation a patient has.
How Unregulated PKA Drives Tumor Growth
Researchers have worked out some of the molecular details of what happens when PKA slips its leash. Laboratory studies using cells with PRKAR1A knocked out show that the loss of this regulatory subunit does not just cause a uniform increase in PKA activity throughout the cell. Instead, it alters the signaling pathway in different ways in different compartments within the cell, leading to a patchwork of disrupted growth signals.5PubMed Central. Inactivation of the Carney complex gene 1 (PRKAR1A) alters spatiotemporal regulation of cAMP and cAMP-dependent protein kinase: a study using genetically encoded FRET-based reporters This compartment-specific dysregulation helps explain why the syndrome produces such a wide variety of tumor types in such different organs.
More recent work has uncovered an additional wrinkle: mutant regulatory subunits can clump together, pulling remaining normal copies of the protein away from their job of keeping catalytic PKA subunits in check. This oligomerization-induced sequestration provides a second, nonclassical route to PKA overactivation that goes beyond the simple “missing protein” model.6PubMed Central. Noncanonical protein kinase A activation by oligomerization of regulatory subunits as revealed by inherited Carney complex mutations In other words, some Carney complex mutations do not just remove a brake pedal; they actively sabotage the braking system through an unexpected mechanism.
Cardiac Myxomas and Their Tendency to Come Back
The most dangerous feature of Carney complex is the cardiac myxoma, a benign heart tumor that can nonetheless cause strokes, embolisms, and sudden death if a piece breaks off and travels through the bloodstream. In the general population, cardiac myxomas are uncommon and almost never recur after surgical removal. In Carney complex, the picture is very different.
Large studies report that roughly 40% of Carney complex patients develop at least one cardiac myxoma. In one cohort of 319 patients, about 43% were affected, with a mean age at diagnosis in the mid-to-late twenties. By age 30, about 35% of women and 45% of men had experienced at least one myxoma.7Genetics in Medicine. Predicting the risk of cardiac myxoma in Carney complex A single-institution study following 38 Carney complex patients over multiple decades found that cardiac myxomas developed in about 63% of their cohort, with the left atrium as the most common location, followed by the right ventricle and right atrium.8PubMed. Cardiac Myxomas in Carney Complex: Single Institution Multidecade Experience The variation in these numbers reflects differences in cohort size, follow-up length, and referral patterns, but the message is consistent: heart tumors are common in this condition.
What truly sets Carney complex apart from sporadic cardiac myxomas is the recurrence rate. In people without the syndrome, the risk of a myxoma coming back after surgery is roughly 2 to 3%. In Carney complex, that number jumps to around 22%, and some studies report even higher figures.9PubMed Central. Keeping Up With Carney Complex: A Case of Recurrent Cardiac Myxomas Over half of myxoma patients in the single-institution series experienced at least one recurrence, with a median time to the first recurrence of about seven and a half years. Recurrences can appear in the same heart chamber or in a completely different one.10PubMed. Cardiac Myxomas in Carney Complex: Single Institution Multidecade Experience The risk is highest in the first several years after surgery and tapers off after about a decade, but male and female patients show different timing patterns: recurrences cluster within about 8 years in males and may take as long as 16 years in females.11Genetics in Medicine. Predicting the risk of cardiac myxoma in Carney complex
Skin Signs as an Early Diagnostic Clue
Carney complex often announces itself on the skin long before any internal tumor is detected. Pigmented skin lesions are present in more than half of all Carney complex patients, and they serve as one of the most visible and diagnostically useful features of the syndrome.12PubMed Central. Carney complex and lentiginosis
The hallmark skin finding is lentiginosis, small flat pigmented spots that look like freckles but tend to appear in distinctive locations: the lips, inner and outer corners of the eyes, the lining of the mouth, and genital skin. Lentigines are reported in roughly 70 to 80% of affected individuals. They typically appear in childhood, darken during puberty, and can fade after the fourth decade of life.13JAMA Dermatology. Oral Pigmentation in McCune-Albright Syndrome Blue nevi, another pigmented lesion, appear in around 40% of patients. In one detailed series of 16 patients, three-quarters had lentiginosis, about 43% had blue nevi, and about 31% had cutaneous myxomas, which are small, benign skin tumors with a jelly-like consistency.14PubMed. Heterogeneity of skin manifestations in patients with Carney complex
These skin findings matter beyond cosmetics. Because they appear early in life, they can prompt the clinical evaluation that uncovers the more dangerous internal manifestations before those cause harm. A young person with unusual lip freckling plus a family history of heart tumors or Cushing syndrome should raise immediate suspicion.
Endocrine Tumors Across Multiple Glands
The endocrine system bears a heavy burden in Carney complex. PKA is a workhorse enzyme in hormone-producing glands, so when it is overactive, several glands can go haywire independently.
Adrenal Glands and Cushing Syndrome
Primary pigmented nodular adrenocortical disease, or PPNAD, is one of the defining features of the syndrome. In PPNAD, both adrenal glands develop tiny pigmented nodules that autonomously produce cortisol, leading to Cushing syndrome, a state of cortisol excess that causes weight gain, muscle weakness, thin skin, high blood pressure, and metabolic disruption.15PubMed. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor Because the cortisol production is independent of the brain’s normal control signals, standard hormone-suppression tests sometimes produce paradoxical results, with cortisol actually rising when it should fall. When PPNAD causes severe Cushing syndrome, the treatment is typically surgical removal of both adrenal glands, as happened in one reported case of a 20-year-old woman whose lentigines and cortisol excess led to the diagnosis.16PubMed Central. Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation
Pituitary Gland and Growth Hormone Excess
The pituitary gland is another common target. In Carney complex, growth-hormone-producing cells in the pituitary can undergo hyperplasia, an overgrowth of otherwise normal-looking tissue, that precedes the formation of true adenomas.17PubMed Central. Pituitary pathology in Carney complex patients This progression from hyperplasia to adenoma may explain why pituitary tumors in Carney complex tend to be microadenomas rather than the larger tumors more commonly seen in sporadic acromegaly.18PubMed. Acromegaly in Carney complex In a recent analysis of 140 Carney complex patients, about 36% showed evidence of growth hormone excess, and about 20% had symptomatic acromegaly, with a median age at diagnosis in the mid-twenties.19The Journal of Clinical Endocrinology & Metabolism. The Spectrum of GH Excess in Carney Complex and Genotype-phenotype Correlations Because acromegaly develops slowly and its early signs, like subtle hand and foot enlargement, are easy to miss, biochemical screening with IGF-1 levels is part of routine surveillance.
Thyroid and Gonadal Tumors
Thyroid abnormalities are among the most common findings in Carney complex, reported in about 75% of patients. These range from benign nodules and follicular adenomas to, occasionally, carcinoma. One case report highlighted multiple follicular adenomas requiring partial thyroidectomy and emphasized the need for ongoing thyroid monitoring given the potential for malignant transformation.20PubMed Central. Carney complex: a case with thyroid follicular adenoma without a PRKAR1A mutation
In males, large-cell calcifying Sertoli cell tumors of the testes are another signature finding, reported in roughly 41% of affected men. These tumors are often bilateral and multifocal, and they can present in adolescence with signs like breast enlargement (gynecomastia) because they sometimes produce estrogen.21PubMed Central. A 14-Year-Old Saudi Boy with Gynecomastia, Cushing Syndrome, Large-Cell Calcifying Sertoli Cell Tumor of the Testis, and Carney Complex While these tumors can also occur sporadically, they are a major diagnostic criterion for Carney complex when found in the right clinical context.22PubMed. Large cell calcifying Sertoli cell tumour: molecular and immunohistochemical assessment of a series comprising non-metastasising and metastasising neoplasms In females, ovarian cystadenomas occur in a smaller fraction, around 14%.23JAMA Dermatology. Oral Pigmentation in McCune-Albright Syndrome
Psammomatous Melanotic Schwannomas
Among the rarer tumors in Carney complex are psammomatous melanotic schwannomas, nerve sheath tumors that contain melanin pigment and calcified granules. These tumors can arise along the spine or peripheral nerves and are associated with Carney complex in about half of all reported cases.24PubMed Central. Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex Although most are benign, they carry a real risk of aggressive behavior: roughly 41% of affected patients experience progression to malignancy, with local recurrence and distant spread both documented.25Journal of Neurosurgery: Spine. Intraspinal psammomatous melanotic schwannoma not associated with Carney complex: case report Anyone diagnosed with one of these unusual tumors should be evaluated for the broader syndrome, since discovering it changes the surveillance and management strategy for the rest of their life.
Diagnosis and the Criteria That Guide It
Carney complex is diagnosed clinically, typically when a patient meets two or more of the major manifestations (cardiac myxoma, PPNAD, lentiginosis in the characteristic distribution, blue nevi, cutaneous or breast myxomas, psammomatous melanotic schwannoma, or large-cell calcifying Sertoli cell tumor, among others). A single major manifestation plus a confirmed PRKAR1A mutation or an affected first-degree relative also meets the diagnostic threshold.26PubMed. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation
Genetic testing for PRKAR1A mutations is now widely available and is recommended for anyone who meets the clinical criteria, as well as for at-risk family members who may be presymptomatic. A positive test result in a relative who appears healthy triggers the start of surveillance protocols, potentially catching heart tumors or hormone abnormalities before they cause complications. However, because the second locus on chromosome 2p16 has not yet been pinned to a specific gene, a negative PRKAR1A test does not completely rule out the condition in a family with a convincing clinical picture.
Lifelong Surveillance
Because Carney complex can produce new tumors at any age, affected individuals need structured, lifelong monitoring across multiple organ systems. Current pediatric and adult surveillance guidelines include regular echocardiograms to catch cardiac myxomas early, with a frequency as often as every six months in higher-risk patients.27PubMed Central. Perioperative Care of a Patient With Carney Complex Thyroid ultrasounds are typically done yearly, and in males, scrotal ultrasounds screen for testicular tumors.28Clinical Cancer Research. Updated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism–Jaw Tumor Syndrome, and Carney Complex Biochemical screening for cortisol excess and growth hormone levels rounds out the endocrine monitoring. A full-body skin examination with a dermatologist every one to two years helps track pigmented lesions and cutaneous myxomas.29PubMed Central. Perioperative Care of a Patient With Carney Complex
The aim of all this monitoring is early intervention. Cardiac myxomas, for instance, are treatable surgically, but the surgery is far safer when the tumor is found on a routine echocardiogram than when it announces itself with a stroke. Similarly, catching Cushing syndrome early prevents years of metabolic damage. The challenge is sustaining this surveillance over a lifetime, since the conditions that need monitoring differ by age and sex, and the discipline of keeping up with frequent appointments can be difficult for patients and families.
Conditions That Look Similar
Several other genetic syndromes share individual features with Carney complex, which can create diagnostic confusion. Peutz-Jeghers syndrome, for example, also causes mucosal lentigines, including on the lips, starting in childhood. However, Peutz-Jeghers is primarily associated with gastrointestinal polyps and cancer risk rather than heart tumors and endocrine overactivity. The lentigines in Peutz-Jeghers tend to be found on the fingers, palms, and soles in addition to the mouth, and while both conditions’ spots can fade with age, the clinical consequences diverge sharply.30JAMA Dermatology. Oral Pigmentation in McCune-Albright Syndrome
McCune-Albright syndrome is another condition that can overlap clinically, involving endocrine overactivity and pigmented skin lesions. But McCune-Albright produces large, irregular café-au-lait spots with jagged borders rather than the small, round lentigines typical of Carney complex, and it is caused by a different signaling pathway altogether.31JAMA Dermatology. Oral Pigmentation in McCune-Albright Syndrome Multiple endocrine neoplasia type 1 (MEN1) shares the pituitary tumor component but does not typically produce heart myxomas or the characteristic skin freckling. Recognizing which constellation of features a patient carries is the key to arriving at the right diagnosis, and by extension, the right surveillance strategy.
What Animal Models Have Revealed
Much of what we know about why specific organs develop tumors in Carney complex comes from genetically engineered mice with tissue-specific deletion of Prkar1a. When the gene was knocked out specifically in the pituitary, nearly half of those mice developed pituitary tumors, compared to about 18% of control animals. The tumors in knockout mice were not just more frequent; they were also different in character, often staining for multiple hormones and associated with elevated growth hormone levels even before a visible tumor formed.32Molecular Endocrinology. Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis
An even more dramatic result came from pancreatic knockouts. When Prkar1a was deleted in all pancreatic cells, every single mouse developed pancreatic neuroendocrine tumors by six months of age, with signs of local invasion and occasional spread to lymph nodes. Their median survival was significantly shorter than controls.33Endocrine-Related Cancer. Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis Pancreatic neuroendocrine tumors are not a major feature of human Carney complex, which highlights an important limitation of mouse models: the tissue-specific consequences of losing PRKAR1A do not map perfectly between species. Still, these models have been invaluable for understanding how PKA overactivation drives tumor formation and for testing potential therapeutic strategies targeting the PKA pathway.